PON1 and laryngotracheoesophageal cleft: Given our prior knowledge on how systemic serum PON1 activity is diminished in LC patients and mouse model profiled with high serum PON1 fucosylation (Ahn et al., 2014; Aldonza et al., 2017), we hypothesized that therapy-induced protein glycosylation rewires the maturation steps of PON1 in the secretory pathway (Figure 4A).